Evidence map›Paper›PMID 33109125›Full record

Observational studyBMC dermatology2020

Actinic keratoses in subjects from la Mitad del Mundo, Ecuador.

Martha Fors, Paloma González, Carmen Viada, Kirsten Falcón, Santiago Palacios

Abstract readObservational Study
In one paragraph

Observational study in BMC dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Skin health of community-living older people: a scoping review.Archives of dermatological research · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Martha ForsUniversidad de Las Américas (UDLA), Redondel del Ciclista, Antigua Vía a Nayón, Quito, Ecuador. martha.fors@udla.edu.ec.ORCID 0000-0002-0844-199X
Paloma GonzálezUniversidad de Las Américas (UDLA), Redondel del Ciclista, Antigua Vía a Nayón, Quito, Ecuador.
Carmen ViadaCentro de Inmunología Molecular, Habana, Cuba.
Kirsten FalcónUniversidad de Las Américas (UDLA), Redondel del Ciclista, Antigua Vía a Nayón, Quito, Ecuador.
Santiago PalaciosPontificia Universidad del Ecuador (PUCE), Quito, Ecuador.

Funding

Universidad de Las Americas MED.MF.17.08.
6 · The paper itself

Abstract

backgroundQuito, the capital of Ecuador due to its geographical location, has a high skin cancer incidence. Actinic keratoses, as premalignant lesions, are precursors of nonmelanoma skin cancer, and the prevalence of this medical condition in the country is unknown.

methodsAn observational, cross-sectional study was performed to assess the prevalence of actinic keratoses (AKs) in a rural area of Quito. Visual skin exams, dermoscopy and biopsy of suspicious lesions were performed.

resultsA total of 254 subjects older than 40 years old (71.3% female) were enrolled. The general AK prevalence was 22.4%; in women, the prevalence was 23.6%, while in men, it was 19.4%. The prevalence rates of basocellular and squamous cell carcinomas and Bowen disease were 1.6, 0.8 and 0.4%, respectively. No statistical associations were found between AKs and the studied variables.

conclusionsThis study was the first reporting the prevalence of premalignant lesions in Ecuador. We could not demonstrate a relationship between the presence of AKs and any of the known risk factors for their development.

Indexed as

AdultAgedBasal Cell CarcinomaBowen's DiseaseCarcinoma, Squamous CellCross-Sectional StudiesEcuadorFemaleHumansKeratosis, ActinicMaleMiddle AgedPrevalenceRisk FactorsSex DistributionSkin NeoplasmsSunscreening AgentsActinic keratoses (AKs)Cross-sectional studyEpidemiologyRisk factors

Identifiers

PMID33109125
PMCPMC7590729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.